Skip to main content

Table 2 Studies reporting PAI-1 activity levels (IU/mL) and major adverse cardiovascular events and restenosis

From: Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis

 

Event

No Event

Reference

Year

Study Design

Follow-up (months)

Population of interest

N

PAI-1 Activity (U/mL)

Range

Death

MI

Restenosis

N

PAI-1 Activity (U/mL)

Range

Sane et al. [50]

1991

Cohort

24

Fibrinolytics

28

17

16

n/a

n/a

28

328

19

21

Shah et al. [72]

1992

Cohort

9

Elective PCI

28

8

7.1

n/a

n/a

28

40

12

8

Gray et al. [73]

1993

Cohort

0.1

MI

13

20.6

11

n/a

13

n/a

85

20.1

7.9

Malmberg et al. [74]

1994

Case-Control

90

MI

53

23.75

13.34

20

33

n/a

55

18

10.97

Brack et al. [75]

1994

Cohort

4

Elective PCI

16

4.63

4.71

n/a

n/a

16

30

5.77

5.06

Nordt et al. [54]

1998

Cohort

12

Fibrinolytics

5

8.7

8.3

n/a

5

n/a

26

9.9

8.2

Jansson et al. [76]

1998

Cohort

120

MI

54

9.1

5.1

54

n/a

n/a

69

10.6

7.1

Wiman et al. [77]

2000

Case-Control

3

MI

61

22.1

17.5

n/a

61

n/a

95

18.2

16.5

Wiman et al. [77]

2000

Case-Control

3

Ml

25

15.4

13.6

n/a

25

n/a

38

17.8

12.4

Prisco et al. [78]

2001

Cohort

18

MI

18

11.27

7.64

n/a

n/a

18

36

15.8

27.49

Prisco et al. [78]

2001

Cohort

18

Elective PCI

6

8.33

8.1

n/a

n/a

6

42

7.57

9.52

Sargento et al. [79]

2003

Cohort

12

MI

7

6.34

1.56

5

2

n/a

80

4.47

1.84

Marcucci et al. [19]

2006

Case-Control

22 2

MI

109

22

9.09

54

55

n/a

411

24.25

10.63

Schoebel et al. [80]

2008

Cohort

2

MI

18

3.7

1.8

n/a

n/a

18

42

5.3

3.2

  1. Wiman et al. [77] is presented twice as data for men and women were reported separately